Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
1.36 (USD) • At close January 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 2.75 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.717 | 0 | 1.961 | 0.756 | 0.21 | 0.108 | 0.06 | 0.083 |
| Cost of Revenue
| 0 | 0.255 | 0.248 | 0.227 | 0.478 | 0.449 | 0.448 | 0.41 | 0.352 | 0.282 | 0.268 | 0.113 | 0.12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | -0.255 | -0.248 | 2.523 | -0.478 | -0.449 | -0.448 | -0.41 | -0.352 | -0.282 | -0.268 | -2.83 | -0.12 | 1.961 | 0.756 | 0.21 | 0.108 | 0.06 | 0.083 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0.917 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.042 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 6.172 | 6.115 | 7.586 | 7.606 | 11.22 | 11.086 | 9.712 | 10.386 | 9.103 | 9.528 | 7.591 | 7.417 | 11.959 | 3.759 | 3.347 | 3.336 | 2.09 | 2.558 | 4.06 |
| General & Administrative Expenses
| 5.627 | 6.409 | 6.448 | 5.828 | 6.635 | 7.208 | 6.804 | 7.097 | 7.239 | 6.319 | 6.189 | 5.945 | 15.822 | 3.46 | 2.607 | 1.818 | 0.845 | 0.892 | 1.407 |
| Selling & Marketing Expenses
| 0 | 0 | -0.248 | -0.227 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 5.627 | 6.409 | 6.2 | 5.601 | 6.635 | 7.208 | 6.804 | 7.097 | 7.239 | 6.319 | 6.189 | 5.945 | 15.822 | 3.46 | 2.607 | 1.818 | 0.845 | 0.892 | 1.407 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 11.799 | 12.524 | 13.786 | 13.207 | 17.855 | 18.294 | 16.516 | 17.483 | 16.342 | 15.847 | 13.78 | 13.362 | 27.781 | 7.219 | 5.954 | 5.154 | 2.935 | 3.45 | 5.467 |
| Operating Income
| -11.799 | -12.524 | -14.034 | -13.434 | -17.855 | -18.294 | -16.516 | -17.483 | -16.342 | -15.847 | -13.78 | 5.771 | -27.781 | -5.258 | -5.198 | -4.944 | -2.827 | -3.39 | -5.384 |
| Operating Income Ratio
| 0 | 0 | 0 | -4.885 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.124 | 0 | -2.681 | -6.876 | -23.543 | -26.176 | -56.5 | -64.867 |
| Total Other Income Expenses Net
| -0.923 | -0.837 | -0.745 | -0.621 | -0.477 | -0.37 | -0.316 | 0.099 | 0.027 | 0.035 | 0.015 | 0.017 | -0.882 | -0.226 | -0.357 | -0.8 | -0.051 | 0.682 | 0.045 |
| Income Before Tax
| -12.722 | -13.361 | -14.779 | -14.055 | -18.332 | -18.664 | -16.832 | -17.384 | -16.315 | -15.812 | -13.765 | -13.345 | -28.663 | -5.484 | -5.555 | -5.744 | -2.878 | -2.708 | -5.339 |
| Income Before Tax Ratio
| 0 | 0 | 0 | -5.111 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.912 | 0 | -2.797 | -7.348 | -27.352 | -26.648 | -45.133 | -64.325 |
| Income Tax Expense
| 0 | 0 | -7.296 | -6.957 | -9.135 | -9.361 | -8.46 | -0.041 | -0.107 | 0.154 | 0.063 | -0.122 | 0.037 | 0.001 | 0.043 | 0.012 | 0.005 | 0.006 | 0.011 |
| Net Income
| -6.783 | -6.805 | -7.483 | -7.098 | -9.197 | -9.303 | -8.372 | -17.343 | -16.208 | -15.966 | -13.828 | -13.223 | -3.142 | -5.485 | -5.598 | -16.703 | -2.883 | -2.714 | -5.35 |
| Net Income Ratio
| 0 | 0 | 0 | -2.581 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.867 | 0 | -2.797 | -7.405 | -79.538 | -26.694 | -45.233 | -64.458 |
| EPS
| -0.24 | -0.26 | -0.29 | -0.27 | -0.36 | -0.37 | -0.33 | -0.7 | -0.66 | -0.66 | -0.65 | -0.68 | -0.16 | -0 | -0.3 | -0.89 | -0.15 | -0.14 | -0.29 |
| EPS Diluted
| -0.24 | -0.26 | -0.29 | -0.27 | -0.36 | -0.37 | -0.33 | -0.7 | -0.66 | -0.66 | -0.65 | -0.68 | -0.16 | -0 | -0.3 | -0.89 | -0.15 | -0.14 | -0.29 |
| EBITDA
| -11.126 | -11.83 | -13.237 | -12.532 | -16.538 | -16.949 | -15.177 | -16.254 | -15.611 | -15.69 | -13.654 | -13.233 | -28.433 | -5.187 | -5.231 | -5.544 | -2.67 | -2.556 | -5.186 |
| EBITDA Ratio
| 0 | 0 | 0 | -4.803 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.166 | 0 | -2.645 | -6.634 | -22.981 | -24.722 | -53.8 | -62.277 |